A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF ; volume:16 ; number:1 ; day:18 ; month:1 ; year:2024 ; pages:1-19 ; date:12.2024
Alzheimer's research & therapy ; 16, Heft 1 (18.1.2024), 1-19, 12.2024
- Urheber
-
Bigi, Alessandra
Napolitano, Liliana
Vadukul, Devkee M.
Chiti, Fabrizio
Cecchi, Cristina
Aprile, Francesco A.
Cascella, Roberta
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-023-01361-z
- URN
-
urn:nbn:de:101:1-2024033110274010280688
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.09.20252025, 20:07 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bigi, Alessandra
- Napolitano, Liliana
- Vadukul, Devkee M.
- Chiti, Fabrizio
- Cecchi, Cristina
- Aprile, Francesco A.
- Cascella, Roberta
- SpringerLink (Online service)
Ähnliche Objekte (12)
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Amyloid blood biomarker detects Alzheimer's disease
Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer’s disease
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Toxic epibatidine was structurally modified to image Alzheimer´s disease
Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Amyloid blood biomarker detects Alzheimer's disease
Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer’s disease
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Toxic epibatidine was structurally modified to image Alzheimer´s disease
Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Amyloid blood biomarker detects Alzheimer's disease
Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer’s disease
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Toxic epibatidine was structurally modified to image Alzheimer´s disease
Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease